The data in the present study demonstrate increased expression of heart failure molecular markers, reduced expression of SERCA2, and impairment of cardiomyocyte contraction in a severe mouse model of SMA. This evidence concerns the gene ATP2A2 and proximal spinal muscular atrophy.